根据Evaluate Pharma 预测,2025 年全球细胞疗法(广义,包括非基因编 辑细胞疗法)市场将达到 175 亿美元。 我们假设 90%市场份额为经基因编 辑的细胞疗法,则对应市场为 157.5 亿美元;假设每剂细胞疗法售价(全 球平均)为 35 万美元,对应约有 4.5 万名患者接受了经基因编辑的细胞疗 法; 根据ASGCT 报告,截至 2022...
The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.More... Sector Health Care Industry Biotechnology Employees 486 Founded 1993 Address 409 Illinois Street San Francisco, CA,...
Despite the revelation, the analysts stick by their buy rating, but lower the price target from $316 to $279. Accompanying theannouncementof the delay in the multiport system, Intuitive alsoreportedits Q422 quarterly earnings of $1.23 per share, missing theZacks Consensus Estimateof $1.26 per ...